Results 141 to 150 of about 297,565 (330)

Strand discrimination in DNA mismatch repair.

DNA Repair, 2021
C. Putnam
semanticscholar   +1 more source

Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy

Advanced Science, EarlyView.
A vitiligo‐derived gene signature predicts response to immune checkpoint blockade across multiple cancer cohorts, providing a framework for patient stratification. Building on this, Fulvestrant—a clinically approved estrogen receptor degrader—further enhances antitumor immunity by reprogramming tumor‐associated macrophages and promoting CD8⁺ T cell ...
Jie Zhu, Liting Huang, Suzhen Bi, WeiKaixin Kong, Wanting Feng, Yingjia Li, Zhengwei Xie, Peipei Shan, Sujie Zhu   +8 more
wiley   +1 more source

MRE11A: a novel negative regulator of human DNA mismatch repair

Cellular & Molecular Biology Letters
Background DNA mismatch repair (MMR) is a highly conserved pathway that corrects DNA replication errors, the loss of which is attributed to the development of various types of cancers. Although well characterized, MMR factors remain to be identified.
Demin Du, Yueyan Yang, Yuanyuan Zhang, Guanxiong Wang, Liying Chen, Xiaowei Guan, Lene Juel Rasmussen, Dekang Liu   +7 more
doaj   +1 more source

tRNA‐Derived Fragment tRF‐22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
tRF‐22 fosters an immunosuppressive and pro‐oncogenic tumor microenvironment in ESCC by stabilizing hnRNPAB against TRIM25‐mediated ubiquitination and enhancing TGFβ2 expression, which increases PMN‐MDSCs infiltration and suppresses CD8+ T cells. Targeting tRF‐22 or blocking TGFβ signalling improves anti‐PD1 response, offering a promising therapeutic ...
Ling Pan, Xin Qin, Li Gong, Haining Liu, Bo Cheng, Jing Wang, Yajie Hu, Lingxing Zeng, Yiping Wang, Qingxu Song, Yufeng Cheng   +10 more
wiley   +1 more source

DNA mismatch repair deficient (dMMR) endometrial cancer

Taiwanese Journal of Obstetrics & Gynecology, 2022
Chia-Hao Liu, Szu-Ting Yang, Peng-Hui Wang   +2 more
doaj   +1 more source

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Journal of Clinical Oncology, 2018
M. Overman, S. Lonardi, K. Wong, H. Lenz, F. Gelsomino, M. Aglietta, M. Morse, E. Cutsem, R. McDermott, A. Hill, M. Sawyer, A. Hendlisz, Bart, Neyns, M. Svrcek, R. Moss, J. Ledeine, Z. Cao, S. Kamble, S. Kopetz, T. André   +20 more
semanticscholar   +1 more source

CLAE: A High‐Fidelity Nanopore Sequencing Strategy for Read‐Level Viral Variant Detection and Environmental RNA Virus Discovery

Advanced Science, EarlyView.
High‐fidelity Nanopore sequencing offers a cost‐effective, portable path to uncovering viral dark matter in complex environments—but suffers from severe read‐length bias, low throughput, and limited accuracy. This study traces these limitations to core biochemical barriers and introduces CLAE, a foundational high‐fidelity platform that enables accurate,
Hannah Yu, Sarah Golconda, Ga‐Eun Lee, Dantong Xue, Guillermo Domínguez‐Huerta, James M. Wainaina, Benjamin Bolduc, Shashanka Murthy, Shihyoung Kim, Seth Faith, Shan‐Lu Liu, Jiyoung Lee, Michael Oglesbee, Matthew B Sullivan, Sanggu Kim   +14 more
wiley   +1 more source

Human MutL homolog (MLH1) function in DNA mismatch repair: a prospective screen for missense mutations in the ATPase domain [PDF]

, 2004
Aaron R. Ellison
openalex   +1 more source

Supplementary Data from Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and <i>O</i>⁶-methylguanine-DNA methyltransferase activity

, 2023
Terzah M. Horton, Gaye Jenkins, Debananda Pati, Linna Zhang, M. Eileen Dolan, Albert Ribes‐Zamora, Alison A. Bertuch, Susan M. Blaney, Shannon L. Delaney, Madhuri Hegde, Stacey L. Berg   +10 more
openalex   +1 more source

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

The Lancet Oncology, 2017
M. Overman, R. McDermott, J. Leach, S. Lonardi, H. Lenz, M. Morse, J. Desai, A. Hill, M. Axelson, R. Moss, Monica V. Goldberg, Z. Cao, J. Ledeine, G. Maglinte, S. Kopetz, T. André   +15 more
semanticscholar   +1 more source